CAd3-ZEBOV
CAd3-ZEBOV
CAd3-ZEBOV (pronounced: CAD-three-ZEBOV) is a vaccine developed for the prevention of the Ebola virus disease. It is a type of recombinant vaccine that uses a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted.
Etymology
The name "CAd3-ZEBOV" is an abbreviation of the full scientific name. "CAd3" stands for "Chimpanzee Adenovirus type 3", which refers to the type of adenovirus used as the vector in the vaccine. "ZEBOV" is an abbreviation for "Zaire Ebola Virus", which is the specific strain of the Ebola virus that the vaccine is designed to protect against.
Development and Use
CAd3-ZEBOV was developed by the National Institutes of Health (NIH) in the United States and GlaxoSmithKline (GSK). The vaccine was first tested in humans in 2014 during the Ebola virus epidemic in West Africa. It has been shown to be safe and effective in inducing an immune response against the Ebola virus.
Related Terms
- Vaccine
- Ebola virus disease
- Recombinant vaccine
- Adenovirus
- National Institutes of Health
- Ebola virus epidemic in West Africa
External links
- Medical encyclopedia article on CAd3-ZEBOV
- Wikipedia's article - CAd3-ZEBOV
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski